Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWAmoxicillin is an orally bioavailable, semisynthetic β-lactam antibiotic.1 It inhibits the growth of 30 isolates of P. mirabilis and 89% of 30 E. coli strains when used at concentrations greater than or equal to 5 and 10 µg/ml, respectively, but resistance develops in strains of Klebsiella, Enterobacter, and indole-positive Proteus species.2 Amoxicillin is susceptible to bacterial β-lactamases but is active against β-lactamase-producing bacteria when used in combination with β-lactamase antibiotics such as clavulanic acid with MIC values of greater than 4,096 and 16 µg/ml without or with clavulanic acid, respectively, against 46 clinical isolates of β-lactamase-producing E. coli.1 Formulations containing amoxicillin have been used in the treatment of a variety of bacterial infections.
WARNING This product is not for human or veterinary use.
1. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob. Agents Chemother. 39(11), 2478-2483 (1995).
2. Amoxicillin, a new penicillin antibiotic. Antimicrob. Agents Ch. 3(2), 262-265 (1973).